Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Impact of IPT With Sulfadoxin Pyrimetamin on Pregnant Women and Their Babies Outcomes in Peri-urban Areas of Bobo-Dioulasso(Burkina Faso)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr Mamoudou Cisse, Centre Muraz
ClinicalTrials.gov Identifier:
NCT01255605
First received: December 6, 2010
Last updated: June 15, 2012
Last verified: June 2012

December 6, 2010
June 15, 2012
September 2010
Not Provided
Peripheral and placental malaria [ Time Frame: Peripheral malaria : at antenatal clinics and at delivery. Placental malaria: at delivery ] [ Designated as safety issue: No ]
The investigators will check if pregnant women have any malaria parasites by making a finger prick thick respectively at antenatal clinics and at delivery. A placental thin smear will be made at delivery.
Peripheral and placental malaria [ Time Frame: At delivery ] [ Designated as safety issue: No ]
The investigators will check if pregnant women have any malaria parasites at delivery by making a finger prick thick and placental thin smear
Complete list of historical versions of study NCT01255605 on ClinicalTrials.gov Archive Site
Maternal anemia, congenital malaria,low birth weight, prematurity. [ Time Frame: Maternal anemia: at antenatal clinics and at delivery. Congenital malaria: at delivery. Low birth weight: at delivery. Prematurity: at delivery. ] [ Designated as safety issue: No ]

The investigators will check pregnant women haemoglobin level.A level< 11g/dl will be considered as anemia.

Congenital malaria will be assessed through cord blood smear. Birth weight <2500g will be considered as low birth weight. Prematurity designs any birth before 37 gestation weeks.

Maternal aneamia, low birth weight, prematurity [ Time Frame: At delivery ] [ Designated as safety issue: No ]
The investigators will check pregnant women haemoglobin level a level< 11g/dl will be considered as anaemia birth weight<2500g will be considered as low birth weight prematurity designs any birth before 37 gestation weeks
Not Provided
Not Provided
 
Impact of IPT With Sulfadoxin Pyrimetamin on Pregnant Women and Their Babies Outcomes in Peri-urban Areas of Bobo-Dioulasso(Burkina Faso)
Impact of Intermittent Preventive Treatment (IPT) With Sulfadoxine-pyrimethamine (SP) on the Morbidities Associated With Malaria in Pregnant Women and Newborns in Peri-urban Areas of Bobo-Dioulasso, 5 Years After Its Adoption by the National Program for Fight Against Malaria in Burkina Faso.

The purpose of this is to determine the impact of intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) on the morbidities associated with malaria in pregnant women and newborns in rural peri-urban areas of Bobo-Dioulasso, 5 years after its implemented.

Malaria in pregnant women is a crucial issue in Burkina Faso. Faced with this problem, a strategy based on the use of treated nets and intermittent preventive treatment (IPT) based on sulfadoxine-pyrimethamine (SP) was adopted in 2005. Five years after its implementation, the investigators will check whether this strategy is still effective in the preventing maternal and congenital malaria on the one hand and maternal anemia, low birth weight and prematurity on the other hand.

Observational
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:

The investigators make thick and thin blood smear and collect a few drops of blood on the 3MM paper Whatmann Schleicher-Schuell.

Probability Sample

Our study population is constitued by pregnant women coming for antenatal care or delivery in two peripheral heath facilities of Bobo-Dioulasso(Lafiabougou and Secteur 24).

Malaria, Pregnancy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
772
June 2011
Not Provided

Inclusion Criteria:

  • Residing in the health area of Lafiabougou or secteur 24
  • Having agreed to give free and informed consent

Exclusion Criteria:

  • Bleeding from during the pregnancy
  • eclampsia
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Burkina Faso
 
NCT01255605
PIC/INSSA/UPB-01
Yes
Dr Mamoudou Cisse, Centre Muraz
Université Polytechnique de Bobo-Dioulasso
Not Provided
Principal Investigator: Mamoudou Cisse, MD Centre MURAZ Research Institute
Université Polytechnique de Bobo-Dioulasso
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP